In-vivo indices of CYP2D6 activity:: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma

被引:35
作者
Chládek, J
Zimová, G
Beránek, M
Martínková, J
机构
[1] Charles Univ, Fac Med, Dept Pharmacol, Hradec Kralove, Czech Republic
[2] Charles Univ, Fac Hosp, Dept Clin Biochem & Diagnost, Hradec Kralove 50002, Czech Republic
关键词
D O I
10.1007/s002280000218
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Dextromethorpan (DM) is widely used as a probe drug to assess in vivo the activity of the cytochrome P450 2D6 (CYP2D6). The aim of the study was to compare metabolic ratios (MRs) of DM to dextrorphan (DEX) in plasma and urine. We examined, separately in urine and plasma, the relationships between the MRs which are based on DEX and those involving the sum of DEX and a secondary metabolite hydroxymorphinan (HM). Furthermore, we compared the MRs in plasma obtained with and without hydrolysis of DEX glucuronides. Methods: Concentrations of DM and metabolites in urine and plasma were determined by HPLC after a single oral dose of 30 mg DM hydrobromide to 101 healthy Caucasian subjects. Urine was collected over the time interval 0-4 h after the dose and plasma was obtained from 95 subjects 3 h after administration. Results. Six subjects (5.9%) were of poor metaboliser (PM) phenotype (urinary DM:DEX ratio >0.3). A good correlation (r(2) = 0.777, P < 0.00001) was observed between the metabolic ratios of DM:DEX in plasma and urine. There was an excellent correlation, both in plasma and urine, between the log-transformed ratios of DM:DEX and of DM to the sum of molar concentrations of DEX and HM (r(2) > 0.996, P < 0.00001). Plasma samples of 89 subjects (83 EM and 6 PM) were analyzed without deconjugation of DEX glucuronide also. The correlation between the plasma ratios of DM:DEX glucuronide (r(2) = 0.793, P < 0.00001) was comparable to that reported by other authors on urine. Conclusion. In healthy Caucasian subjects, the MRs of DM to DEX in plasma obtained at 3 h correlated reasonably well with those in urine collected over the time interval 0-4 h after the dose. Nevertheless, repeatability of this plasma index should be determined before its wide use can be recommended. Finally, the interindividual variation in DEX metabolism to HM (catalyzed by CYP3A) contributes only minimally to the interindividual variability of the MRs.
引用
收藏
页码:651 / 657
页数:7
相关论文
共 32 条
[1]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[2]   Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan [J].
Basci, NE ;
Bozkurt, A ;
Kayaalp, SO ;
Sayal, A ;
Isimer, A .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1998, 23 (01) :1-5
[3]   The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans [J].
Capon, DA ;
Bochner, F ;
Kerry, N ;
Mikus, G ;
Danz, C ;
Somogyi, AA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (03) :295-307
[4]   Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects [J].
Chládek, J ;
Zimová, G ;
Martínková, J ;
Tuma, I .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1999, 13 (04) :508-515
[5]   DEXTROMETHORPHAN O-DEMETHYLATION IN LIVER-MICROSOMES AS A PROTOTYPE REACTION TO MONITOR CYTOCHROME-P-450 DB1 ACTIVITY [J].
DAYER, P ;
LEEMANN, T ;
STRIBERNI, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (01) :34-40
[6]   Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians [J].
Droll, K ;
Bruce-Mensah, K ;
Otton, SV ;
Gaedigk, A ;
Sellers, EM ;
Tyndale, RF .
PHARMACOGENETICS, 1998, 8 (04) :325-333
[7]  
DUCHE JC, 1993, INT J CLIN PHARM TH, V31, P392
[8]   Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data [J].
Gaedigk, A ;
Gotschall, RR ;
Forbes, NS ;
Simon, SD ;
Kearns, GL ;
Leeder, JS .
PHARMACOGENETICS, 1999, 9 (06) :669-682
[9]   CHARACTERIZATION OF DEXTROMETHORPHAN N-DEMETHYLATION BY HUMAN LIVER-MICROSOMES - CONTRIBUTION OF THE CYTOCHROME-P450 3A (CYP3A) SUBFAMILY [J].
GORSKI, JC ;
JONES, DR ;
WRIGHTON, SA ;
HALL, SD .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (01) :173-182
[10]   Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population [J].
Griese, EU ;
Zanger, UM ;
Brudermanns, U ;
Gaedigk, A ;
Mikus, G ;
Morike, K ;
Stuven, T ;
Eichelbaum, M .
PHARMACOGENETICS, 1998, 8 (01) :15-26